Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
BTX's Cash to Debt is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. BTX: No Debt )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.33
BTX's Equity to Asset is ranked higher than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BTX: 0.33 )
BTX' s 10-Year Equity to Asset Range
Min: -45.87   Max: 0.99
Current: 0.33

-45.87
0.99
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
86% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -4.02
M-Score: -2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1262.63
BTX's Operating margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. BTX: -1262.63 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -1262.63

-9788.46
-116.83
Net-margin (%) -989.69
BTX's Net-margin (%) is ranked higher than
56% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. BTX: -989.69 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -989.69

-9471.15
-137.48
ROE (%) -296.49
BTX's ROE (%) is ranked higher than
50% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. BTX: -296.49 )
BTX' s 10-Year ROE (%) Range
Min: -894.2   Max: -29.3
Current: -296.49

-894.2
-29.3
ROA (%) -76.01
BTX's ROA (%) is ranked higher than
55% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. BTX: -76.01 )
BTX' s 10-Year ROA (%) Range
Min: -821.71   Max: -21
Current: -76.01

-821.71
-21
ROC (Joel Greenblatt) (%) -1867.41
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. BTX: -1867.41 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33633.33   Max: -400
Current: -1867.41

-33633.33
-400
Revenue Growth (%) -3.90
BTX's Revenue Growth (%) is ranked higher than
72% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 115.4
Current: -3.9

0
115.4
EBITDA Growth (%) 63.40
BTX's EBITDA Growth (%) is ranked higher than
99% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. BTX: 63.40 )
BTX' s 10-Year EBITDA Growth (%) Range
Min: -48.9   Max: 63.9
Current: 63.4

-48.9
63.9
EPS Growth (%) 42.50
BTX's EPS Growth (%) is ranked higher than
97% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. BTX: 42.50 )
BTX' s 10-Year EPS Growth (%) Range
Min: -35.6   Max: 67.1
Current: 42.5

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.20
BTX's P/B is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. BTX: 11.20 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 11.2

5.65
83
P/S 28.90
BTX's P/S is ranked higher than
67% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. BTX: 28.90 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 28.9

4.83
124
EV-to-EBIT -3.56
BTX's EV-to-EBIT is ranked higher than
59% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BTX: -3.56 )
BTX' s 10-Year EV-to-EBIT Range
Min: 36   Max: 93.1
Current: -3.56

36
93.1
Current Ratio 1.65
BTX's Current Ratio is ranked higher than
56% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. BTX: 1.65 )
BTX' s 10-Year Current Ratio Range
Min: 0.02   Max: 76
Current: 1.65

0.02
76
Quick Ratio 1.60
BTX's Quick Ratio is ranked higher than
59% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. BTX: 1.60 )
BTX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 74
Current: 1.6

0.02
74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
BTX's Price/Median PS Value is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BTX: 0.90 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 15.6
Current: 0.9

0.14
15.6
Forward Rate of Return (Yacktman) 46.59
BTX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. BTX: 46.59 )
BTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.5   Max: 21.5
Current: 46.59

4.5
21.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany
BioTime, Inc. was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. The Company has historically developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. Its focus is in the field of regenerative medicine; specifically human embryonic stem ("hES") cell and induced pluripotent stem ("iPS") cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. The Company plans to develop stem cell products for research and therapeutic use through its subsidiaries. OncoCyte Corporation is developing products and technologies to diagnose and treat cancer. ES Cell International Pte., Ltd. ("ESI"), a Singapore private limited company, develops and sells hES products for research use. BioTime Asia, Limited a Hong Kong company, sells products for research use and may develop therapies to treat cancer, neurological, and orthopedic diseases. OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc., formerly known as Embryome Sciences, Inc. is developing therapies to treat vascular and blood diseases and disorders. Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. markets GeneCards, the human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. Its products for use in stem cell research are being offered to researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. As of March 18, 2013, the company owned or controlled or licensed directly or through its subsidiaries 281 issued or allowed U.S. patents and also owned or controlled over 141 pending U.S. patent applications, including provisional patent applications, to protect its proprietary technologies. The Company also licensed 140 IP patents and applications from WARF. The Company and its subsidiaries face competition in both blood plasma expander business and regenerative medicine and stem cell business.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer... Jul 31 2014
9:04 am BioTime subsidiary OncoCyte expands clinical development of bladder cancer diagnostic by... Jul 31 2014
BIOTIME INC Files SEC form 8-K, Other Events Jul 31 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer... Jul 31 2014
Asterias Biotherapeutics Announces Live Investor Webcast Jul 24 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Jul 14 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.12 and the... Jul 10 2014
BIOTIME INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jul 07 2014
BioTime subsidiary Asterias Biotherapeutics raises $12.5M Jun 17 2014
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jun 17 2014
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Jun 12 2014
BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger... Jun 12 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Jun 02 2014
BioTime to Present at the Jefferies 2014 Global Healthcare Conference Jun 02 2014
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 30 2014
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership... May 30 2014
BioTime unit settle patent interference proceedings May 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide